anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Experiencing a diagnosis of cancer may dramatically alter the way a person feels about themselves, their body, and their significant relationships at sexual and intimate levels1. Cancer and its treatments affect the physiological, psychological, and sociological realms of a survivor's life and his/her ability to experience sexual health. Sexual health is recognized as an integral aspect of quality of life (QOL) during cancer and is increasingly receiving research and clinical attention. Sexual changes following the treatment of gynaecologic (i.e.: ovarian, endometrial, cervical) and colorectal cancers are common though often not discussed. Moreover, cancer survivors express dissatisfaction that sexual concerns, and treatment of them, are not discussed in the context of their cancer care. Oncologists frequently are faced with patients inquiring about sexual changes with cancer treatment, but are usually not equipped with accurate and comprehensive data on the precise sexual symptoms to expect or where to refer patients with sexual concerns.

The aims of the study are to assess the efficacy of a 12-module online psychoeducational intervention for sexual health (OPES) on (1) the primary endpoint of sexual distress in male and female cancer survivors with sexual problems; (2) the secondary sexuality-related endpoints of sexual desire, arousal (women) or erection (men), orgasm, and sexual pain; (3) on mood, relationship satisfaction, and quality of life; and (4) to assess gender differences in the proportion of survivors improved on sexual distress.
RESEARCH QUESTION: Is intra-abdominal fat obesity associated with infertility?
DESIGN: This study analysed data from the 2013-2018 National Health and Nutrition Examination Survey, with a total of 3013 women enrolled. The participants were divided into two groups: infertility and non-infertility. Differences between the two groups were analysed using a weighted Student's t-test or Mann-Whitney U-test for continuous variables, or a weighted chi-squared test for categorical data. Visceral adipose tissue area (VATA) was assessed by dual-energy X-ray absorptiometry. The independent association between infertility and log VATA was assessed by weighted multivariate logistic regression models. Subgroup analyses were performed to assess the strength of the results. Interaction tests were used to examine whether covariates interacted with log VATA to influence infertility.
RESULTS: Log VATA was significantly higher in the infertility group compared with the non-infertility group (P < 0.001). After adjustment for potential confounders, the results of multivariate logistic regression analysis revealed that an increase in log VATA was associated with increased prevalence of female infertility (OR = 2.453, 95% CI 1.278-4.792). Subgroup analyses showed this association in individuals aged <35 years (P = 0.002), Mexican-Americans (P = 0.033), non-hypertensive individuals (P = 0.013) and non-diabetic individuals (P = 0.003).
CONCLUSIONS: An enlarged VATA is associated with increased risk of infertility. The direct effect of VATA on female infertility needs to be clarified further to provide a basis for future prevention and treatment of female infertility.
The invention provides milk-derived active peptide GITDPLFKGM, GITDPLFKG, and an acquisition method and application thereof. The invention firstly provides a milk-derived active peptide GITDPLFKGM which comprises a peptide with a sequence shown as SEQ ID NO. 1; SEQ ID NO.1: gly-Ile-Thr-Asp-Pro-Leu-Phe-Lys-Gly-Met. The invention also provides a milk-derived active peptide GITDPLFKG which comprises a peptide with a sequence shown as SEQ ID NO. 2; SEQ ID NO.2: gly-Ile-Thr-Asp-Pro-Leu-Phe-Lys-Gly. The milk active peptide provided by the invention has higher antioxidation capability and better immunoregulation capability.
Infection of immature mice with rhinovirus (RV) induces an asthma-like phenotype consisting of type 2 inflammation, mucous metaplasia, eosinophilic inflammation, and airway hyperresponsiveness that is dependent on IL-25 and type 2 innate lymphoid cells (ILC2s). Doublecortin-like kinase 1-positive (DCLK1+) tuft cells are a major source of IL-25. We sought to determine the requirement of tuft cells for the RV-induced asthma phenotype in wild-type mice and mice deficient in Pou2f3, a transcription factor required for tuft cell development. C57BL/6J mice infected with RV-A1B on day 6 of life and RV-A2 on day 13 of life showed increased DCLK1+ tuft cells in the large airways. Compared with wild-type mice, RV-infected Pou2f3-/- mice showed reductions in IL-25 mRNA and protein expression, ILC2 expansion, type 2 cytokine expression, mucous metaplasia, lung eosinophils, and airway methacholine responsiveness. We conclude that airway tuft cells are required for the asthma phenotype observed in immature mice undergoing repeated RV infections. Furthermore, RV-induced tuft cell development provides a mechanism by which early-life viral infections could potentiate type 2 inflammatory responses to future infections.
The method for the conservative treatment of fibrous cystic mastopathy by mesotherapy and autohemotherapy comprises the basic therapy, namely vitamins, adaptogens, sedatives, dehydration drugs, 0.25% solution of potassium iodide, antiestrogens, hepatotropic drugs, and cholagogues. Prior to the basic therapy, detoxifying therapy is performed using enterosorbent Bilosorb, 3 tablets twice a day after meals, and the probe-free tubage for 10 days. The basic therapy comprises complex antihomotoxic drugs prescribed step-by-step. The following mixture of antihomotoxic drugs is used: Ovarium compositum, Hepar compositum, Coenzyme compositum, Thyreoidea compositum, Echinacea compositum. The drugs are injected in the autogenous blood intracutaneously in the acupuncture points ??36, RP6, periumbilical and ovarian areas, 10 injections in total. Phytocompositions are prescribed on an individual basis changing the herbal compositions every month. The overall duration of the treatment is up to 3 months.
The invention provides a traditional Chinese medicine for treating infantile pneumonia. The traditional Chinese medicine comprises the following raw materials in definite proportioning by weight: radix codonopsis, dried orange peels, tendrilleaf fritillary bulbs, rhizome of large-headed atractylodes, heartleaf houttuynia herbs, stemona roots, tatarian aster roots, platycodon roots, common andrographis herbs and licorice root. The preparation formulation of the traditional Chinese medicine disclosed by the invention can be any kind of oral solutions, powder, tablets and capsules. The traditional Chinese medical science believes that clearing the heat, freeing the lung, tonifying the spleen and relieving the cough should be used as a treating principle for treating the infantile pneumonia. The formula of the traditional Chinese medicine for treating the infantile pneumonia, disclosed by the invention, contains traditional Chinese medicines for clearing the heat, freeing the lung, tonifying the spleen and relieving the cough. The medicines are in drug compatibility for use and in synergistic reaction, so that the purpose of treating the infantile pneumonia is achieved.
Paste (A) for treating dermatological diseases of the oral mucosa comprises as active agent a virustatic compound (I) in an anhydrous base, i.e. a hypromellose adhesive paste consisting of a dry substance (II) and a gel. An independent claim is also included for a paste, or active ingredient (or combination) compressed into a tablet, for treating dermatological diseases of the oral mucosa, incorporated into an anhydrous base. ACTIVITY : Virucide. No details of tests for virucidal activity are given. MECHANISM OF ACTION : None are given.
The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
Subjects will complete BREAST-Q Pre-Op (Qol) survey and Pain Distribution survey prior to Surgery. Subjects will in the RPNI arm will undergo mastectomy with breast reconstruction surgery with regenerative peripheral nerve interface. Subjects will complete BREAST-Q Post-Op (QoL) survey and Pain Distribution Survey at Months 1, 3, 6, and 12 post-surgery. Information about the patient and course of care will be collected from electronic medical records.
BACKGROUND: Proline-rich tyrosine kinase 2 (PYK2) is involved in the occurrence, proliferation, migration, and invasion of various tumors. However, few studies have reported the role of PYK2 in colorectal cancer (CRC).
AIM: To explore the effects of PYK2 on CRC metastasis and elucidate the detailed molecular mechanisms involved.
METHODS: The expression and prognosis value of PYK2 in CRC prognosis were analyzed using data from The Cancer Genome Atlas (TCGA). PYK2 was knocked down or overexpressed in human CRC cell line, HCT116. Cell proliferation, migration, invasion, and cycle changes were analyzed using CCK-8, Transwell, and flow cytometry assays. Western blotting and quantitative real-time PCR were performed to detect the mRNA and protein levels of cell proliferation and epithelial-mesenchymal transition (EMT) indicators. Fluorescence staining was performed to examine the cytoskeleton.
RESULTS: Lower expression of PYK2 was observed in CRC tissues and associated with poor prognosis and metastasis in patients with CRC in TCGA database. PYK2 knockdown significantly induced the migration and invasion of CRC cells but did not affect cell proliferation or cycle. Immunofluorescence staining of phalloidin showed that the downregulation of PYK2 increased the cytoskeleton in CRC cells. Moreover, low expression of PYK2 induced the downregulation of E-cadherin and upregulation of snail and vimentin by activating Wnt/β-catenin signaling, thus promoting EMT in CRC cells.
CONCLUSIONS: Low PYK2 expression was found in tumor tissues, especially metastases, and significantly correlated with patient prognosis. Moreover, decreased PYK2 induces EMT by activating Wnt/β-catenin signaling, which is the potential mechanism of CRC metastasis. Regulating the expression of PYK2 to suppress tumor cell metastasis may represent a promising therapeutic strategy for metastatic CRC.
Initiation of STRIBILD in patients with estimated creatinine clearance below 70 mL per min is not recommended. Because STRIBILD is a fixed-dose combination tablet, STRIBILD should be discontinued if estimated creatinine clearance declines below 50 mL per minute during treatment with STRIBILD as dose interval adjustment required for emtricitabine and TDF cannot be achieved [see Warnings and Precautions (5.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14)].

No data are available to make dose recommendations for pediatric patients with renal impairment.

Clinical Trials in Adult Subjects with Mild to Moderate Renal Impairment

In Study 118, 33 HIV-1 infected treatment-naïve subjects with mild to moderate renal impairment (eGFR by Cockcroft-Gault method between 50 and 89 mL/minute) were studied in an open-label clinical trial evaluating the safety of 48 weeks of treatment with STRIBILD. After 48 weeks of treatment, the mean change in serum creatinine was 0.17 ± 0.14 mg/dL and the mean change in eGFR by Cockcroft-Gault method was −6.9 ± 9.0 mL/minute for subjects treated with STRIBILD.

Twelve of the 33 subjects studied had baseline eGFR between 50 and 70 mL/minute. Three subjects, all with baseline eGFR between 50–60 mL/minute, discontinued STRIBILD due to a renal adverse event. The safety of STRIBILD among 21 of the 33 subjects with baseline eGFR greater than or equal to 70 mL/minute was consistent with the safety profile in studies 102 and 103.
PURPOSE: Medical school educators face challenges determining which new and emerging topics to incorporate into medical school curricula, and how to do so. A study was conducted to gain a better understanding of the integration of emerging topics related to microbiology and immunology in the undergraduate medical curriculum (UME).
METHODS: An anonymous survey with 17 questions was emailed to medical school faculty who teach immunology and/or microbiology through the DR-Ed listserv, the American Society for Microbiology (ASM) Connect listserv, and attendees of the Association of Medical School Microbiology and Immunology Chairs (AMSMIC) Educational Strategies Workshop. Participants were asked about experiences, perceptions, and the decision-making process regarding integrating emerging topics into UME.
RESULTS: The top emerging topics that were added to the curriculum or considered for addition in the last 10 years included COVID-19, Zika virus, mRNA vaccines, and Mpox (formerly known as monkeypox). Most respondents reported lectures and active learning as the major methods for topic delivery, with most faculty indicating that formative assessment was the best way to assess emerging topics. Content experts and course directors were the most cited individuals making these decisions. Top reasons for incorporating emerging topics into curricula included preparing students for clinical treatment of cases, followed by demonstrating the importance of basic science, and opportunities to integrate basic science into other disciplines. Challenges for incorporating these topics included making room in an already crowded curriculum, followed by content overload for students.
CONCLUSIONS: This study describes the rationale for integrating emerging topics related to microbiology and immunology into UME, and identifies the current new and emerging topics, as well as the main methods of integration and assessment. These results may be used by medical educators to inform curricular decisions at their institutions. Future studies will include developing innovative learning modules that overcome barriers to integration.
The invention relates to a pharmaceutical preparation for treating and preventing pharyngitis and application thereof. The pharmaceutical preparation is prepared from Rhizoma Atractylodis Macrocephalae, Radix Platycodi, Fructus Arctii, Bidens parviflora Willd., Ornithogalum caudatum Jacq. , Fructus Forsythiae, Andrographis laxiflora (Bl.) Lindau , Periostracum Cicadae, Fructus Gardeniae, Bulbus Fritillariae Cirrhosae, Radix Glycyrrhizae, Hydrocotyle sibthorpioides, Folium Isatidis, and Herba Taraxaci. The geo-authentic crude drugs are selected, and based on the traditional Chinese medicine theory, the compatibility is reasonable, yin and yang are balanced, various medicinal materials are matched to achieve the effects of diminishing inflammation, eliminating phlegm and relieving cough, and the treatment effect for pharyngitis patients is remarkable. In an animal model experiment, the treatment effect of the pharmaceutical preparation provided by the invention is significantly higher than that of a model control group, and the treatment effects of a high-dosage composition and a middle-dosage composition are significantly higher than that of a positive control group. The clinical experiment results show that the preparation product provided by the invention has a cure rate of 85 percent or more and an effective rate of 99 percent or more, has no toxic and side effects, and is suitable for clinical popularization and application.
Primary Objectives: There are three study goals. First, the investigators will determine the safety of a 36 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend). This 36 month (n=10) pilot study will extend the prior 2 month observation tests towards the goal of assessing the safety of Leukine for treatment of Parkinson's disease (PD). Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera panel). Second, the investigators will assess regimen tolerability administered in a dose reduction, from 6 µg/kg/day without interruption, to 3 µg/kg/day with 2 day drug holidays. The lowered dose was chosen based on known tolerability and parallel-linked immune reconstitution seen in cancer-associated disease treatments. Due to fragility of the patient population and prior recorded adverse events the proposed dose reductions are justified.

Secondary Objectives:

Over a course of 36 months, the effects of treatment on defined adaptive immune deficits in PD as measured by analysis of peripheral blood mononuclear cells collected before, during, and after cessation of Leukine administration will be examined. Individual T cell parameters that include links between T cell function and subset analyses and clinical neurological signs and symptoms will be examined. These immune parameters will be serially examined as they may contribute to the immune deficits in PD. Thus, timed analyses of changes in T cell phenotypes and/or function will be completed. In addition, the investigators will assess the functional stability of the immune deficits in PD and will determine whether the immune deficits of PD are consistent during baseline data collection. The potential Leukine-induced motor control and mobility improvements will be determined by assessing UPDRS part I, II, III, and IV scores off treatment and on treatment. Specifically, over the course of this six-month treatment study, various biomarkers will be assessed including: T cell markers of immune activation, DNA methylation status, and B cell and bone marrow progenitor cell markers. We hope to uncover the time course of Treg induction, as well as link the pharmacokinetics of Leukine treatment (not previously recorded) to changes in specific biomarkers. Additionally, changes in the humoral response following extended Leukine treatment will be assessed by measuring the presence of antibodies against Leukine and alterations in B cell frequencies.
Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
Epiregulin (EREG) is a member of the epidermal growth factor (EGF) family. An increasing body of evidence has demonstrated the pivotal role of EREG in the pathogenesis and progression of various malignancies. However, the clinical significance and biological role of EREG in pancreatic ductal adenocarcinoma (PDAC) have yet to be fully elucidated. We found that EREG is highly expressed in PDAC tissues compared with paracancerous tissues through public databases and clinical samples. High EREG expression predicted worse overall survival (OS) and recurrence-free survival (RFS) in patients with PDAC. Multivariate analysis revealed that EREG can serve as an independent prognostic indicator. In addition, EREG silencing inhibited PDAC cell proliferation, migration, progression, altered cell cycle, facilitated apoptosis in vitro and suppressed tumor growth in vivo. Conversely, EREG overexpression facilitated the proliferation, migration, and invasion in PaTu-8988 t cell. Through transcriptome sequencing and experimental verification, we found EREG mediates PDAC tumorigenesis through ERK/p38 MAPK signaling pathway. Moreover, we found EREG expression is closely related to PD-L1 expression in PDAC tissues and cells. Therefore, EREG is expected to be a prospective prognostic and therapeutic marker for PDAC.
PROBLEM TO BE SOLVED: To improve an action (an irritation or the like) of a composition to be applied to the mucous membrane such as eye lotion, keeping high refrigerant. SOLUTION: The sense (the irritation or the like) to the mucous membrane caused by a refrigerant component (e.g. menthol, camphor and borneol) is improved by a compound (e.g. caffeine) represented by formula (1) (wherein, R1, R2 and R3 are each a hydrogen atom or an alkyl group which may be substituted) or a pharmaceutically acceptable salt thereof while keeping the refrigerant caused by the refrigerant component. The compound (1) or the salt thereof functions as the agent for improving the sense caused by the refrigerant. The proportion of the compound (1) or the salt thereof is about 0.01-10,000 pts.wt. expressed in terms of a free compound based on 10 pts.wt. refrigerant component.  The refrigerant composition can be usable as the composition to be applied for the mucous membrane (e.g. a liquid preparation such as the eye lotion, an eye wash, a nasal drop and an agent for contact lens, an ointment such as an ointment for the eye).
The present invention involves an analysis of the CopB outer membrane protein of M. catarrhalis. Four CopB antigens now have been sequenced and their predicted amino acid sequences compared. Regions of conservation and non-conservation have been identified in this antigen, including one non-conserved region that represents an antibody binding region from the strain 035E. A single amino acid change (N to D) in this epitope, at residue 295, abolishes reactivity of the antibody 10F3 with CopB. Peptides which only contain residues of this region that are C-terminal to residue 295 do retain reactivity but their reactivity is less than the maximal reactivity achieved in the presence of an asparagine at position 295. Compositions and both diagnostic and immunoprophylactic methods are disclosed.